CN102655876B - α-1蛋白酶抑制剂组合物、方法和试剂盒 - Google Patents

α-1蛋白酶抑制剂组合物、方法和试剂盒 Download PDF

Info

Publication number
CN102655876B
CN102655876B CN201080054535.7A CN201080054535A CN102655876B CN 102655876 B CN102655876 B CN 102655876B CN 201080054535 A CN201080054535 A CN 201080054535A CN 102655876 B CN102655876 B CN 102655876B
Authority
CN
China
Prior art keywords
api
composition
alanine
amino acid
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080054535.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102655876A (zh
Inventor
郭建新
安东尼·克洛什
B·科尔德伦
D·巴尼特
马克·曼宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Grifols Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43970713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102655876(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Therapeutics LLC filed Critical Grifols Therapeutics LLC
Publication of CN102655876A publication Critical patent/CN102655876A/zh
Application granted granted Critical
Publication of CN102655876B publication Critical patent/CN102655876B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201080054535.7A 2009-11-03 2010-11-02 α-1蛋白酶抑制剂组合物、方法和试剂盒 Active CN102655876B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25771109P 2009-11-03 2009-11-03
US61/257,711 2009-11-03
PCT/US2010/055135 WO2011056793A2 (en) 2009-11-03 2010-11-02 Composition, method, and kit for alpha-1 proteinase inhibitor

Publications (2)

Publication Number Publication Date
CN102655876A CN102655876A (zh) 2012-09-05
CN102655876B true CN102655876B (zh) 2015-07-15

Family

ID=43970713

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080054535.7A Active CN102655876B (zh) 2009-11-03 2010-11-02 α-1蛋白酶抑制剂组合物、方法和试剂盒

Country Status (19)

Country Link
US (2) US20130131192A1 (cg-RX-API-DMAC7.html)
EP (1) EP2496246B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013510158A (cg-RX-API-DMAC7.html)
KR (1) KR20120114235A (cg-RX-API-DMAC7.html)
CN (1) CN102655876B (cg-RX-API-DMAC7.html)
AU (1) AU2010315325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012010392B8 (cg-RX-API-DMAC7.html)
CA (1) CA2779369C (cg-RX-API-DMAC7.html)
CL (1) CL2012001159A1 (cg-RX-API-DMAC7.html)
ES (1) ES2679819T3 (cg-RX-API-DMAC7.html)
HU (1) HUE039240T2 (cg-RX-API-DMAC7.html)
IL (1) IL219485A (cg-RX-API-DMAC7.html)
MX (1) MX2012005132A (cg-RX-API-DMAC7.html)
NZ (1) NZ599783A (cg-RX-API-DMAC7.html)
PL (1) PL2496246T3 (cg-RX-API-DMAC7.html)
PT (1) PT2496246T (cg-RX-API-DMAC7.html)
RU (1) RU2555332C2 (cg-RX-API-DMAC7.html)
TR (1) TR201809898T4 (cg-RX-API-DMAC7.html)
WO (1) WO2011056793A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007127A2 (pt) * 2011-12-30 2017-04-04 Grifols Sa métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
IL267520B2 (en) * 2016-12-22 2023-09-01 Kamada Ltd Dry powder composition of alpha-1 antitrypsin
WO2018132874A1 (en) * 2017-01-19 2018-07-26 Csl Limited Method of preventing an immune response with alpha- 1 anti-trypsin
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
US11566031B2 (en) * 2019-03-04 2023-01-31 Tae Life Sciences, Llc Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
MX2022010087A (es) 2020-02-25 2022-09-02 Grifols Worldwide Operations Ltd Procedimiento para obtener un inhibidor de proteinasa alfa-1.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US20050013867A1 (en) * 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5029005B2 (cg-RX-API-DMAC7.html) * 1972-05-08 1975-09-19
JPS51118819A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
JPS597693B2 (ja) 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US5218091A (en) 1982-08-13 1993-06-08 Zymogenetics, Inc. Glycolytic promoters for regulated protein expression: protease inhibitor
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4732973A (en) 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3901917A1 (de) 1989-01-24 1990-07-26 Behringwerke Ag Mutanten von humanem antithrombin iii
GB8913183D0 (en) 1989-06-08 1989-07-26 Central Blood Lab Authority Chemical products
US5079336A (en) 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5032405A (en) 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
JP3479539B2 (ja) 1992-04-10 2003-12-15 エーザイ株式会社 ヒトアンチトロンビンｉｉｉ変異体
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
US5843705A (en) 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
KR20010052345A (ko) 1998-05-12 2001-06-25 수잔 씨 복 인간 항트롬빈 3 및 그에 관련된 방법
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US20040157911A1 (en) 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
AU2001271021A1 (en) 2000-07-05 2002-01-14 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003090682A2 (en) * 2002-04-25 2003-11-06 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
PT1664123E (pt) 2003-09-22 2008-07-16 Kamada Ltd Preparação em larga escala de um inibidor da alfa-1 proteinase e sua utilização
US7691810B2 (en) 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
WO2005049801A2 (en) 2003-11-14 2005-06-02 Arriva Pharmaceuticals, Inc. Dry protein formulation
SI1684719T1 (sl) 2003-11-14 2012-07-31 Baxter Int Sestavki alfa antitripsina in postopki zdravljenja ob uporabi takih sestavkov
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
BRPI0618893A2 (pt) 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
MX2008010173A (es) 2006-02-09 2009-02-12 Kamada Ltd Antitripsina alfa-i para tratar episodios de exacerbacion de enfermedades pulmonares.
JP5810091B2 (ja) 2009-11-24 2015-11-11 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 凍結乾燥方法、組成物、及びキット

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US20050013867A1 (en) * 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations

Also Published As

Publication number Publication date
JP2013510158A (ja) 2013-03-21
CL2012001159A1 (es) 2012-09-14
KR20120114235A (ko) 2012-10-16
CA2779369A1 (en) 2011-05-12
BR112012010392A2 (pt) 2016-07-12
AU2010315325A1 (en) 2012-06-07
EP2496246A2 (en) 2012-09-12
PL2496246T3 (pl) 2018-09-28
MX2012005132A (es) 2012-07-25
RU2012122793A (ru) 2013-12-10
TR201809898T4 (tr) 2018-07-23
PT2496246T (pt) 2018-07-31
JP6030201B2 (ja) 2016-11-24
US9616126B2 (en) 2017-04-11
AU2010315325B2 (en) 2014-11-27
US20130131192A1 (en) 2013-05-23
WO2011056793A2 (en) 2011-05-12
CA2779369C (en) 2018-06-19
IL219485A (en) 2017-06-29
ES2679819T3 (es) 2018-08-31
BR112012010392B1 (pt) 2021-01-05
HUE039240T2 (hu) 2018-12-28
JP2015221835A (ja) 2015-12-10
IL219485A0 (en) 2012-06-28
ES2679819T8 (es) 2019-01-22
EP2496246B1 (en) 2018-06-27
EP2496246A4 (en) 2013-03-27
BR112012010392B8 (pt) 2021-05-25
RU2555332C2 (ru) 2015-07-10
WO2011056793A3 (en) 2011-09-29
NZ599783A (en) 2013-10-25
US20160106843A1 (en) 2016-04-21
CN102655876A (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
US9616126B2 (en) Composition, method, and kit for alpha-1 proteinase inhibitor
ES2758827T3 (es) Formulaciones para enzimas lisosómicas
CN100448482C (zh) Hgf冻干制剂
AU2020203183A1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
KR101880905B1 (ko) 안정한 수성 ｍｉａ／ｃｄ－ｒａｐ 제제
WO1997002832A1 (fr) Preparations lyophilisees de hgf
PT2720710E (pt) Formulações liofilizadas de fgf-18
CN106687126B (zh) 因子viii制剂
KR20210078514A (ko) 항-rsv 항체의 제제 및 그의 사용 방법
AU2020311050B2 (en) Stable formulations of recombinant proteins
EP4065161A1 (en) High concentration formulations of anti-csf1 and anti-csf1r antibodies
KR20110015552A (ko) 건조한 트랜스글루타미나제 조성물
CN119950703B (zh) 抗体制剂
JPH06247870A (ja) インターロイキン−６を含有する医薬製剤
WO2025177156A1 (en) Stable ophthalmic pharmaceutical formulation of aflibercept
RU2776108C2 (ru) Лиофилизированный состав на основе hgf
JP5265514B2 (ja) Ｈｇｆ製剤
EA047252B1 (ru) Стабильные составы рекомбинантных белков

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant